EGFR突变型晚期非小细胞肺癌患者预后因素分析  

Analysis on the Prognostic Factors in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

作　　者：张旭东[1] 董昱[1] 杨晓军[1] ZHANG Xudong;DONG Yu;YANG Xiaojun(Sichuan Cancer Hospital,Chengdu 610041,Sichuan Provinve,China.)

机构地区：[1]四川省肿瘤医院,成都610041

出　　处：《职业卫生与病伤》2018年第4期236-239,共4页Occupational Health and Damage

基　　金：四川省科技支撑项目(项目编号:2011FZ0069)

摘　　要：目的探讨EGFR突变型晚期非小细胞肺癌患者预后的影响因素。方法回顾性分析135例EGFR突变的晚期非小细胞肺癌患者临床资料,采用Kaplan-Meier方法及Cox多因素回归分析预后因素。结果吸烟状况、ECOG评分和EGFR-TKI靶向治疗是影响EGFR突变型晚期非小细胞肺癌患者生存的独立预后因素。结论有EGFR突变的晚期非小细胞肺癌患者应使用EGFR-TKI靶向治疗,并结合体能状况及吸烟史等因素制定治疗方案,有利于控制肿瘤的疾病进展及延长患者生存期。Objective To investigate the prognostic factors in advanced non-small cell lung cancer（ NSCLC）patients with EGFR mutations. Methods The paper retrospectively reviewed the clinical data of 135 advanced NSCLC patients with EGFR mutations,and the prognostic factors were analyzed by the method of Kaplan-Meier and the Cox multivariate proportional hazards model. Results Smoking,ECOG score and EGFR-TKI targeted therapy were the independent predictors of survival for advanced NSCLC patients with EGFR mutations. Conclusion The advanced NSCLC patients with EGFR mutations should receive with the EGFR-TKI targeted therapy,and the physical condition,smoking history should be considered when making the therapeutic regimen,which are beneficial for controlling the disease progress and improving the overall survival.

关 键 词：非小细胞肺癌 生存 预后 

分 类 号：R734.2[医药卫生—肿瘤]